{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:03Z","timestamp":1777934583078,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To gain consensus on the patient assessment skills required by pharmacist independent prescribers prescribing immunomodulators in myeloma across National Health Service Scotland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a two-phase study which used nominal group technique to gain local consensus followed by a two-round eDelphi questionnaire to gain national consensus across all cancer networks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>This project was conducted across the three cancer networks within NHS Scotland: South East Scotland Cancer Network; West of Scotland Cancer Network and North Cancer Alliance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects<\/jats:title>\n                    <jats:p>Participants were invited from each cancer network (South East Scotland Cancer Network, West of Scotland Cancer Network and North Cancer Alliance) and included haematology consultants, haematology specialist registrars, haematology advanced nurse practitioners and haematology pharmacists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were five participants in the nominal group technique. Twenty-two out of 31 patient assessment skills gained local consensus, seven patient assessment skills did not gain consensus and two patient assessment skills were deemed irrelevant. There were 12 and 14 participants in round one and two of the eDelphi questionnaire, respectively. Twenty-nine patient assessment skills were included in the first-round questionnaire and 21 gained consensus. The remaining eight patient assessment skills were included in round two where seven did not achieve consensus and one achieved disagreement consensus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This research outlines 21 patient assessment skills required for pharmacist independent prescribers to prescribe immunomodulators for myeloma patients according to haematology specialists in Scotland. Discussion on patient assessment skills without consensus showed that the pharmacist independent prescribers would have a shared responsibility with the consultant. This work should inform the development of a competency framework to allow training of pharmacist independent prescribers in Scotland. Some patient assessment skills could be transferrable for pharmacist independent prescribers prescribing systemic anti-cancer therapy for other haematological malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221110467","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T01:08:30Z","timestamp":1656464910000},"page":"217-228","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["What patient assessment skills do pharmacist independent prescribers require to prescribe immunomodulators in myeloma?"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-029X","authenticated-orcid":false,"given":"Anton","family":"Slavin","sequence":"first","affiliation":[{"name":"NHS Lothian"},{"name":"Pharmacy, Western General Hospital, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanj","family":"Kurdi","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences"},{"name":"Hawler Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"Wilson","sequence":"additional","affiliation":[{"name":"NHS Lothian"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"The Scottish Medicines Consortium. SMC2289 4th September 2020. https:\/\/www.scottishmedicines.org.uk\/media\/5466\/lenalidomide-revlimid-mm-final-september-2020-for-website.pdf (2020 accessed 20th October 2020)."},{"key":"e_1_3_2_3_2","unstructured":"Myeloma UK. What is myeloma?https:\/\/www.myeloma.org.uk\/understanding-myeloma\/what-is-myeloma\/ (2020 accessed 01 December 2020)."},{"key":"e_1_3_2_4_2","unstructured":"Cancer Research UK. Myeloma statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma (2020 accessed 01 December 2020)."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_3_2_6_2","unstructured":"British Oncology Pharmacist Association and Faculty of Cancer Pharmacy. Oncology pharmacy non-medical prescribing guidelines (Version 4.1). www.bopawebsite.org\/sites\/default\/files\/publications\/BOPA%20Non%20Medical%20Prescribing%20Guidelines%20v4.1%20Aug%202018.pdf (2018 accessed 7th November 2020)."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"West of Scotland Cancer Network. Non-Medical Prescriber Competency framework and Service Development Tool for the Prescribing of SACT (Version 2.1 September 2020). https:\/\/www.intranet.woscan.scot.nhs.uk\/wp-content\/uploads\/2020\/09\/Final_Published_NMP-SACT-PRESCRIBING-FRAMEWORK-v2.1-September-2020.pdf (2020 accessed 7th November 2020).","DOI":"10.12968\/jprp.2020.2.12.692"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219841118"},{"key":"e_1_3_2_9_2","first-page":"25","article-title":"Evaluating a pharmacist prescriber role in haematology and oncology clinics","volume":"23","author":"Duncan N","year":"2017","unstructured":"Duncan N. Evaluating a pharmacist prescriber role in haematology and oncology clinics. J Oncol Pharm Pract2017; 23: 25. Conference Abstract.","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_2_10_2","first-page":"128","article-title":"Improving haematology clinics: chesterfield royal hospital experience","volume":"189","author":"Faulkner R","year":"2020","unstructured":"Faulkner R, Welch E, Tam J, et al.Improving haematology clinics: chesterfield royal hospital experience. Br J Haematol2020; 189: 128\u2013129. Conference Abstract.","journal-title":"Br J Haematol"},{"key":"e_1_3_2_11_2","first-page":"295","article-title":"Impact of a pharmacist independent prescriber (PIP) on the haematology ward at the southern health and social care trust (Craigavon area hospital)","volume":"41","author":"Fox D","year":"2019","unstructured":"Fox D, Agnew J, Palmer J, et al.Impact of a pharmacist independent prescriber (PIP) on the haematology ward at the southern health and social care trust (Craigavon area hospital). Int J Clin Pharm2019; 41: 295\u2013296. Conference Abstract.","journal-title":"Int J Clin Pharm"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100414"},{"key":"e_1_3_2_13_2","unstructured":"Sweiss K Wirth S Park I et al.Collaborative physician-pharmacist multiple myeloma clinic improves guideline adherence and prevents treatment delays. Blood Conference: 59th Annual Meeting of the American Society of Hematology ASH 2017; 130. Conference Abstract."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.314"},{"key":"e_1_3_2_15_2","first-page":"655","article-title":"How to use the nominal group and Delphi techniques","volume":"38","author":"McMillan SS","year":"2016","unstructured":"McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm2016; 38: 655\u2013662. 2016\/02\/06.","journal-title":"Int J Clin Pharm"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-37"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020476"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/NXN.0b013e31825e8923"},{"key":"e_1_3_2_19_2","first-page":"1","article-title":"The Delphi technique: making sense of consensus","volume":"12","author":"Hsu Chia-Chien SB","year":"2007","unstructured":"Hsu Chia-Chien SB. The Delphi technique: making sense of consensus. Practical Assessment, Research, and Evaluation2007; 12: 1\u20138.","journal-title":"Practical Assessment, Research, and Evaluation"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1783\/147118906778586598"},{"key":"e_1_3_2_21_2","unstructured":"Revlimid\u00ae. Summary of manufacturer product characteristics. www.medicines.org (accessed 7 Dec 2020)."},{"key":"e_1_3_2_22_2","unstructured":"The Edinburgh Cancer Centre. SACT protocol for Lenalidomide and dexamethasone for the treatment of multiple myeloma. (2020)."},{"key":"e_1_3_2_23_2","article-title":"Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: assessment and significance","author":"Ali K","unstructured":"Ali K, Al-Quteimat O, Naseem R, et al.Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: assessment and significance. J Oncol Pharm Pract 2020; 27: 815\u2013820.","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_2_24_2","unstructured":"Zakout G Ng HW Panoskaltsis N. A collaborative pharmacist-physician multi-professional pre-chemotherapy assessment in hematology cancer patients is an efficient & cost-effective model for service delivery of outpatient systemic anti-cancer therapy (SACT). Blood Conference: 59th Annual Meeting of the American Society of Hematology ASH 2017; 130. Conference Abstract."},{"key":"e_1_3_2_25_2","first-page":"23","article-title":"How do pharmacists and nurses learn to prescribe-a qualitative study","volume":"23","author":"Abuzour AS","year":"2015","unstructured":"Abuzour AS, Lewis P, Tully M. How do pharmacists and nurses learn to prescribe-a qualitative study. International Journal of Pharmacy Practice2015; 23: 23. Conference Abstract.","journal-title":"International Journal of Pharmacy Practice"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/jan.13375"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/13561820.2017.1394279"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2017.02.002"},{"key":"e_1_3_2_29_2","unstructured":"The Edinburgh Cancer Centre. Service Level Agreement for nurse\/pharmacist led clinic for patients receiving abiraterone with prednisolone for the treatment of metastatic prostate cancer. 2020."},{"key":"e_1_3_2_30_2","unstructured":"The Edinburgh Cancer Centre. Service Level Agreement for nurse\/pharmacist led clinic for patients receiving enzalutamide for the treatment of metastatic castration resistant prostate cancer (mCRPC). 2020."},{"key":"e_1_3_2_31_2","unstructured":"The Edinburgh Cancer Centre. Protocol for Non-medical prescriber (NMP) Led Clinic for Patients receiving CDK4\/6 inhibitors for the treatment of ER positive HER2 negative metastatic breast cancer."},{"key":"e_1_3_2_32_2","unstructured":"The Edinburgh Cancer Centre. Guidance for Non-Medical Prescribing practice within ECC. March 2020."},{"key":"e_1_3_2_33_2","unstructured":"Slavin A. Email sent to: Andrea Preston Macmillan Divisional Lead- Haematology and SW Cancer Commissioning Pharmacist 29th April 2021."},{"key":"e_1_3_2_34_2","unstructured":"The Scottish Governement. Achieving Excellence in Pharmaceutical Care. https:\/\/www.gov.scot\/binaries\/content\/documents\/govscot\/publications\/strategy-plan\/2017\/08\/achieving-excellence-pharmaceutical-care-strategy-scotland\/documents\/00523589-pdf\/00523589-pdf\/govscot%3Adocument\/00523589.pdf?forceDownload=true (2017)."},{"key":"e_1_3_2_35_2","unstructured":"The Royal Pharmaceutical Society. Advanced Pharmacy Framework. https:\/\/www.rpharms.com\/Portals\/0\/RPS%20document%20library\/Open%20access\/Frameworks\/RPS%20Advanced%20Pharmacy%20Framework.pdf (2013)."},{"key":"e_1_3_2_36_2","unstructured":"The Royal Pharmaceutical Society. The Core Advanced Pharmacist Curriculum. 2021."},{"key":"e_1_3_2_37_2","unstructured":"NES Education for Scotland. Prescribing and Clinical Skills. https:\/\/www.nes.scot.nhs.uk\/our-work\/prescribing-and-clinical-skills\/ (2021)."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijpp.12465"},{"key":"e_1_3_2_39_2","unstructured":"The Royal Pharmaceutical Society. A Competency Framework for Designated Prescribing Practitioners. https:\/\/www.rpharms.com\/Portals\/0\/RPS%20document%20library\/Open%20access\/Professional%20standards\/DPP%20Framework\/DPP%20competency%20framework%20Dec%202019.pdf?ver=2019-12-18-150746-160 (2019)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221110467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221110467","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221110467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:13Z","timestamp":1777688833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221110467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/10781552221110467"],"URL":"https:\/\/doi.org\/10.1177\/10781552221110467","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]}}}